Integrated Filing — IndAS



General information about company

Scrip Code 540797
NSE Symbol SHALBY
MSEI Symbol NOTLISTED
ISIN INE597J01018
Name of company SHALBY LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 03-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Healthcare Services
Start date and time of board meeting 03-11-2026   15:28:00
End date and time of board meeting 03-11-2026   15:58:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 03-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.shalby.org/wp-content/uploads/2018/01/Related-Party-Transaction-Policy-v6-2.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There was no default on Loans and there are no debt securities during the quarter ended March 31, 2026



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 24,531.90 49,911.10
Other income 528.70 1,056.20
Total income 25,060.60 50,967.30
2 Expenses
(a) Cost of materials consumed 7,962.10 16,628.20
(b) Purchases of stock-in-trade 471.10 904.80
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (28.10) (60.30)
(d) Employee benefit expense 3,047.90 6,032.80
(e) Finance costs 318.70 626.40
(f) Depreciation, depletion and amortisation expense 1,095.20 2,175.30
(f) Other Expenses
1 Fees To Doctors & Consultants 6,815.90 13,921.80
2 Other Expenses 2,093.60 3,931.50
3 Other Operative Expenses 129.00 263.00
Total other expenses 9,038.50 18,116.30
Total expenses 21,905.40 44,423.50
3 Total profit before exceptional items and tax 3,155.20 6,543.80
4 Exceptional items 0.00 0.00
5 Total profit before tax 3,155.20 6,543.80
6 Tax expense
7 Current tax 971.20 2,119.70
8 Deferred tax (166.40) (433.00)
9 Total tax expenses 804.80 1,686.70
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 2,350.40 4,857.10
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 2,350.40 4,857.10
17 Other comprehensive income net of taxes (4.30) (8.60)
18 Total Comprehensive Income for the period 2,346.10 4,848.50
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 10,751.90 10,751.90
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.19 4.52
Diluted earnings (loss) per share from continuing operations 2.19 4.52
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.19 4.52
Diluted earnings (loss) per share from continuing and discontinued operations 2.19 4.52
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the Unaudited Standalone Financial Results for the Quarter & Half year ended September 30, 2026 1. The above unaudited financial results for the quarter & half year ended September 30, 2026 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the company at their respective meetings held on November 3, 2026. The Statutory Auditors of the Company have carried out a Limited Review for said unaudited financial results. 2. These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter. 3. Shalby Limited Employees Welfare Trust has acquired 7,00,000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme-2021. Till September 30, 2026, Company has granted all 7,00,000 Stock Options to eligible employees, out of which total 4,47,765 Stock Options were lapsed and 2,45,735 options were vested and exercised by eligible employees. In accrodance with the resolution passed by Nomination and Remuneration Committee, the company has granted 1,48,000 stock options from the pool of 4,47,765 lapsed options. As of September 30, 2026, a total of 70,500 stock options remain active. 4. The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated November 26, 2018. 5. The company's operating segment is Medical and Healthcare Related Services. Since the company has a single operating segment, disclosure pertaining to segment as per the regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable. 6. Previous period figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 59,486.70
Capital work-in-progress 26.20
Investment property 0.00
Goodwill 819.70
Other intangible assets 587.70
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 41,472.90
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other Financial Assets 1,046.90
2 Income Tax Assets (Net) 170.40
Total of other non-current financial assets 1,217.30
Total non-current financial assets 42,690.20
Deferred tax assets (net)
Other non-current assets
1 Other non current assets 3,535.80
Total of other non-current assets 3,535.80
Total non-current assets 1,07,146.30
2 Current assets
Inventories 3,031.70
Current financial asset
Current investments 20,046.40
Trade receivables, current 22,522.70
Cash and cash equivalents 1,151.50
Bank balance other than cash and cash equivalents 3.40
Loans, current 0.00
Other current financial assets
Total of other current financial assets 10,278.20
Total current financial assets 54,002.20
Current tax assets (net)
Other current assets
1 Other Current Assets 775.70
Total of other current assets 775.70
Total current assets 57,809.60
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,64,955.90
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 10,755.60
Other equity 1,18,862.80
Total equity attributable to owners of parent 1,29,618.40
Non controlling interest
Total equity 1,29,618.40
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 9,203.70
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liability 792.10
2 Other Financial Liabilities 39.20
Total of other non-current financial liabilities 831.30
Total non-current financial liabilities 10,035.00
Provisions, non-current 798.90
Deferred tax liabilities (net) 7,098.80
Deferred government grants, Non-current
Other non-current liabilities
1 Other Non-current Liabilities 591.70
Total of other non-current liabilities 591.70
Total non-current liabilities 18,524.40
Current liabilities
Current financial liabilities
Borrowings, current 2,358.80
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 351.70
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 11,371.30
Total Trade payable 11,723.00
Other current financial liabilities
1 Lease Liability 248.20
2 Other Financial Liabilities 1,300.50
Total of other current financial liabilities 1,548.70
Total current financial liabilities 15,630.50
Other current liabilities 819.80
1 Other Current liabilities 819.80
Total of other current liabilities 819.80
Provisions, current 362.80
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 16,813.10
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 35,337.50
Total equity and liabilites 1,64,955.90
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 A. (i) Items that will not be reclassified to profit or (loss)] (5.80) (11.50)
Total Amount of items that will not be reclassified to profit and loss (5.80) (11.50)
2 Income tax relating to items that will not be reclassified to profit or loss (1.50) (2.90)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income (4.30) (8.60)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 6,543.80
Adjustments for reconcile profit (loss)
Adjustments for finance costs 626.40
Adjustments for decrease (increase) in inventories (568.20)
Adjustments for decrease (increase) in trade receivables, current (4,577.40)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (174.60)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 8.00
Adjustments for other financial assets, current 32.10
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,339.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (215.70)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,175.30
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 40.00
Adjustments for provisions, non-current 141.00
Adjustments for other financial liabilities, current 7.30
Adjustments for other financial liabilities, non-current (52.90)
Adjustments for unrealised foreign exchange losses gains (1.90)
Adjustments for dividend income 0.00
Adjustments for interest income 443.10
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (156.90)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 189.30
Share of profit and loss from partnership firm or association of persons or limited liability partnerships (24.60)
Total adjustments for reconcile profit (loss) (1,656.90)
Net cash flows from (used in) operations 4,886.90
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 4,886.90
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 2,750.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 37.30
Purchase of property, plant and equipment 819.40
Proceeds from sales of investment property 22,456.00
Purchase of investment property 21,489.30
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 480.30
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 3.80
Net cash flows from (used in) investing activities (2,081.30)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 734.00
Repayments of borrowings 1,151.10
Payments of lease liabilities 163.00
Dividends paid 0.00
Interest paid 583.60
Income taxes paid (refund) 1,829.20
Other inflows (outflows) of cash 3.70
Net cash flows from (used in) financing activities (2,989.20)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (183.60)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (183.60)
Cash and cash equivalents cash flow statement at beginning of period 1,335.10
Cash and cash equivalents cash flow statement at end of period 1,151.50





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Shalby Limited Dr Darshini V Shah Relative of Key Management Personnel Purchase of goods or services NA 128.10 24.70 140.00
2 Shalby Limited Dr. Nishita Shukla Key Management Personnel Remuneration NA 62.20 0.00 0.00
3 Shalby Limited Dr. Vikram I. Shah Promoter and Key Management Personnel Purchase of goods or services NA 91.60 9.50 108.40
4 Shalby Limited Mr Amit Kumar Key Management Personnel Remuneration NA 37.40 0.00 0.00
5 Shalby Limited Mr Shanay Shah Promoter and Key Management Personnel Remuneration NA 43.80 0.00 0.00
6 Shalby Limited Tushar Shah Key Management Personnel Remuneration NA 19.70 0.00 0.00
7 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Any other transaction Profit Share NA 24.60 0.00 0.00
8 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Interest received NA 12.80 0.00 0.00
9 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Investment NA 0.00 220.50 239.70
10 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Purchase of goods or services NA 5,018.20 2,129.70 2,294.70
11 Shalby Limited Griffin Mediquip LLP Subsidiary Entity Any other transaction Rent Income NA 3.60 0.20 0.00
12 Shalby Limited Shalby Medtech Limited Subsidiary Entity Any other transaction Loan Given NA 6,550.00 0.00 0.00
13 Shalby Limited Shalby Medtech Limited Subsidiary Entity Any other transaction Loan Recevied NA 3,800.00 5,500.00 8,250.00
14 Shalby Limited Shalby Medtech Limited Subsidiary Entity Investment NA 0.00 0.00 0.00
15 Shalby Limited Shalby Medtech Limited Subsidiary Entity Interest received NA 311.30 0.00 0.00
16 Shalby Limited Shalby Medtech Limited Subsidiary Entity Investment NA 0.00 12,500.00 12,500.00
17 Shalby Limited Shalby Advanced Technologies, Inc. Step-down Subsidiary company Any other transaction Advance for Exp NA 0.00 0.00 0.00
18 Shalby Limited Shalby Advanced Technologies, Inc. Step-down Subsidiary company Any other transaction Corporate Guarantee NA 99.70 0.00 0.00
19 Shalby Limited Shalby Advanced Technologies, Inc. Step-down Subsidiary company Any other transaction Reimbursement of Exp on behalf of Subcidiary NA 100.90 0.00 0.00
20 Shalby Limited Shalby Hospitals Mumbai Pvt. Ltd. Subsidiary Entity Investment NA 0.00 0.00 0.00
21 Shalby Limited Shalby International Limited Subsidiary Entity Investment NA 0.00 5.00 5.00
22 Shalby Limited Shalby Kenya Limited Subsidiary Entity Purchase of goods or services NA 16.90 0.00 0.00
23 Shalby Limited Shalby Kenya Limited Subsidiary Entity Investment NA 0.00 0.60 0.60
24 Shalby Limited Shalby Orthopedic Hospital and Research Centre Enterprise over which KMP/Relatives of KMP exercise significant influence through controlling interest (Other related Party) Any other transaction Rent Income NA 3.00 0.50 3.20
25 Shalby Limited Slaney Healthcare Pvt. Ltd. Subsidiary Entity Investment NA 0.00 112.10 112.10
26 Shalby Limited Slaney Healthcare Pvt. Ltd. Subsidiary Entity Any other transaction Royalty NA 78.80 344.20 0.00
27 Shalby Limited Vrundavan Shalby Hospitals Limited Subsidiary Entity Investment NA 0.00 2,297.30 2,297.30
28 Shalby Limited Vrundavan Shalby Hospitals Limited Subsidiary Entity Any other transaction Rent Income NA 1.50 0.00 0.00
29 Shalby Limited Yogeshwar Healthcare Limited Subsidiary Entity Investment NA 0.00 0.00 0.00
30 Shalby Limited Zodiac Mediquip Limited Promotor Company Any other transaction Guest House usage charges NA 5.10 5.00 10.50
31 Shalby Limited Shalby Medtech Limited Subsidiary Entity Any other transaction ESOP Compensation expenses NA 13.60 0.00 0.00
32 Shalby Limited Dr. Vikram I. Shah -Professional Fee Promoter and Key Management Personnel (KMP) Purchase of goods or services NA 42.70 7.20 45.60
33 Shalby Limited PK Healthcare Private Limited Subsidiary Company Investment NA 0.00 16,152.20 16,152.20
34 Shalby Limited PK Healthcare Private Limited Subsidiary Company Any other transaction Corp. Loan Given NA 0.00 2,000.00 2,000.00
35 Shalby Limited PK Healthcare Private Limited Subsidiary Company Any other transaction Corp. Loan Recevied back NA 0.00 0.00 0.00
36 Shalby Limited PK Healthcare Private Limited Subsidiary Company Interest received NA 86.20 0.00 0.00
37 Shalby Limited PK Healthcare Private Limited Subsidiary Company Any other transaction Sale of Fixed Assets NA 0.00 0.00 0.00
38 Shalby Limited PK Healthcare Private Limited Subsidiary Company Any other transaction Corporate Guarantee Commission NA 33.90 0.00 0.00
39 Shalby Limited PK Healthcare Private Limited Subsidiary Company Any other transaction ESOP Compensation expenses NA 0.00 0.00 0.00
40 Shalby Limited Healers Healthcare Private Limited Subsidiary Company Investment NA 0.00 10,400.00 10,400.00
41 Shalby Limited Shalby Medtech Limited Subsidiary Company Any other transaction Corporate Gurantee NA 31.10 0.00 0.00
42 Shalby Limited Slaney Healthcare Pvt. Ltd. Subsidiary Company Any other transaction ESOP Compensation expenses NA 1.00 0.00 0.00
43 Shalby Limited Healers Healthcare Private Limited Subsidiary Company Any other transaction Corporate Gurantee NA 41.60 0.00 0.00
44 Shalby Limited Shalby Hospitals Mumbai Pvt. Ltd. Subsidiary Company Any other transaction Dr. Fees Reimbursement NA 0.50 1.00 1.50
45 Shalby Limited PK Healthcare Private Limited Subsidiary Company Purchase of fixed assets NA 0.00 12.30 0.00
46 Shalby Limited PK Healthcare Private Limited Subsidiary Company Sale of goods or services NA 0.00 0.00 0.00
47 Shalby Limited Shalby Medtech Limited Subsidiary Company Any other transaction Rent Expense NA 201.30 104.30 0.00
48 Shalby Limited Shalby Medtech Limited Subsidiary Company Purchase of goods or services NA 0.00 31.10 0.00
Total value of transaction during the reporting period 16,861.10